News Focus
News Focus
Replies to #68578 on Biotech Values
icon url

apljack

11/14/08 11:01 PM

#68588 RE: ghmm #68578

Late Stage Products looking for a home

I couldn't negotiate the editing language to make some minor changes to the list.

JAV's US Dyloject is not intranasal, this is injectible diclofenac. JAV also has a P3 drug that IS intranasal: Ketamine (Ereska) that is due for an NDA in 2009.

aj
icon url

ghmm

11/15/08 8:20 AM

#68597 RE: ghmm #68578

Late Stage Products looking for a home

EDITS: Fixed Ketamine, Added TNFerade, updated update instructions

Criteria
1. Unparterned
2. Not enough cash to bring the product to market
3. Lets say at least started Phase 3 trials
4. Its on a product basis so if company a has 2 unparterned Phase 3 products and not enough cash then an entry for each would be appropriate
 
Stock Product Stage Comments
----- --------------- --------------------- -----------------------------
NTII Viprinex Phase 3 Interim analysis January '09. Stroke Drug, high chance of failure.
BPAX Libigel Phase 3 ~2010 Submit Adequate Safety?
EPIX Vasovist PDUFA 12/30/08 FDA initially rejected saying 2 more studies needed. Allowed reread company states
results very positive. Looking to sell outright on approval.
RPRX Proellex Phase 3 Uterine fibroids
CHTP Droxidopa Pivotal Phase III Orthostatic hypotension. Results expected 02/09
JAV Dyloject Phase III Approved in UK. Post operative Pain (injectable)
JAV Ketamine Phase III Acute moderate-to-severe pain (intranasal)
GNVC TNFerade Pivotal Phase III Pancreatic cancer

-----
Updating the list
1. Reply to this post copying all the text
2. Changed the "EDITS:" to account for changes, e.g. Edits: Added Viprinex
3. Please put [ pre ] at the begining of the table without surrounding spaces are "pre".
4. Please put [ /pre ] at the end of the table without surrounding spaces around "pre".